Home
News
Screeners
Insights
Emmessar Biotech
23.
58
-0.91
(-3.72%)
Market Cap
₹11.84 Cr
PE Ratio
31.00
Industry
Chemicals
Buy
Sell
Company Performance:
1D
-3.72%
1M
-3.76%
6M
-6.06%
1Y
-13.37%
5Y
0.00%
View Company Insights
Latest news about Emmessar Biotech
Emmessar Biotech to hold AGM on Sept 29; reappoints MD, WTD
8 days ago
Emmessar Biotech schedules its 34th AGM for September 29, 2026. Shareholders to reappoint MD Srinivasa Raghavan Mathurakavi Ayyangar for five years. WTD Jeyavel Balaiah Nadar seeks reappointment until February 2031. Remote e-voting opens on September 26 with a cutoff date of September 22.
Emmessar Biotech sets 34th AGM for September 29 via video conferencing
Aug 27, 2026
Emmessar Biotech & Nutrition net profit rises 23% in Q1FY27
Aug 08, 2026
Emmessar Biotech FY26 Net Profit Rises to ₹43.59 Lacs
May 13, 2026
Emmessar Biotech & Nutrition Limited confirms non-applicability of SEBI circular regarding funding by large corporates
Apr 08, 2026
More news about Emmessar Biotech
08
Apr 26
Emmessar Biotech & Nutrition Limited Submits Q4FY26 SEBI Compliance Certificate
Emmessar Biotech & Nutrition Limited filed its Q4FY26 compliance certificate under SEBI Regulation 74(5) on 8th April, 2026, covering the quarter ended 31st March, 2026. The certificate from registrar MUFG Intime India Private Limited confirms proper handling of securities dematerialisation processes, including timely confirmation of securities to depositories, proper certificate mutilation procedures, and adherence to prescribed timelines for member register updates.
11
Feb 26
Emmessar Biotech & Nutrition Limited Reports Q3 FY26 Financial Results
Emmessar Biotech & Nutrition Limited reported net profit of ₹11.64 lakhs for Q3 FY26, marking a significant increase from ₹1.72 lakhs in the corresponding quarter last year. Revenue from operations was ₹9.34 lakhs while total income reached ₹58.32 lakhs. For the nine-month period, the company achieved net profit of ₹40.17 lakhs on total income of ₹184.06 lakhs. The results were approved by the Board on February 11, 2026.
12
Nov 25
Emmessar Biotech Nutrition Reports Q2 FY2026 Results: Revenue Dips, Records Quarterly Loss
Emmessar Biotech Nutrition Limited released unaudited Q2 FY2026 results, ending September 30, 2025. Revenue decreased to ₹9.26 lakhs from ₹13.90 lakhs in Q1. The company reported a net loss of ₹3.67 lakhs, compared to a profit of ₹30.55 lakhs in Q1. H1 FY2026 showed total revenue of ₹23.16 lakhs and net profit of ₹26.88 lakhs. The company operates in healthcare and real estate sectors. Results were approved by the Board on November 12, 2025.
Emmessar Biotech
23.
58
-
0.
91
(-
3.
72
%)
1 Year Returns:
-13.37%
Industry Peers
Deepak Fertilisers & Petrochemicals
1,320.40
(-
1.
14
%)
Tata Chemicals
612.45
(+
0.
31
%)
Gujarat Narmada Valley Fert & Chem
562.40
(-
1.
46
%)
TANFAC Industries
3,379.55
(-
0.
13
%)
Gujarat Alkalies & Chemicals
705.00
(-
1.
91
%)
GHCL
421.15
(-
0.
84
%)
Grauer & Weil
75.60
(-
1.
15
%)
Chemplast Sanmar
171.35
(-
2.
72
%)
Fischer Medical Ventures
35.87
(+
2.
78
%)
JG Chemicals
592.05
(-
0.
50
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar